ProCE Banner Activity

Stroke Risk Reduction and Outcomes With Novel Therapies in Diabetes Care

Clinical Thought

Diabetes significantly increases first and recurrent stroke risk and worsens outcomes post stroke, including higher mortality and poorer recovery. Learn about new data for the benefits of GLP-1 receptor agonists and SGLT2 inhibitors for stroke risk reduction in patients with type 2 diabetes.

Released: August 26, 2024

Expiration: August 25, 2025

Share

Faculty

Alejandro A. Rabinstein

Alejandro A. Rabinstein, MD, FAHA

Professor of Neurology
Chair, Hospital Neurology and Neurocritical Care Division
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Disclosure

Primary Author

Alejandro A. Rabinstein, MD, FAHA

Professor of Neurology
Chair, Hospital Neurology and Neurocritical Care Division
Mayo Clinic
Rochester, Minnesota

Alejandro A. Rabinstein, MD, FAHA: advisory board: Brainomix, Chiesi, Shionogi; other financial or material support: Boston Scientific.